Clinical Trial

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Study acronym: AlphaBet
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial will evaluate the safety of Radium-223 in combination with 177Lu-PSMA-I\&T in metastatic castration-resistant prostate cancer: Phase I/II study
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-16; most recent amendment 2025-02-05.
Status change: Recruiting → Active, Not Recruiting 2025-02-05
Status change: Not Yet Recruiting → Recruiting 2022-09-26
Trial Details
NCT Number NCT05383079
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Metastatic Castration-resistant Prostate Cancer, MCRPC, Prostate Cancer
Enrollment 36 participants
Start Date 2022-09-13
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-07